
Ataxia telangiectasia mutated (ATM)-deficient chronic lymphocytic leukemia (CLL), often caused by deletion of chromosome 11q, accounts for about 20
To develop and evaluate a PK/PD model that mechanistically describes the competitive interaction between intravenous (IV) fentanyl and intranasal (IN) naloxone at brain μ-opioid receptors (MORs) and simulates reversal of respiratory depression. A compartmental PK/PD model incorporating central, peripheral, brain and nasal compartments was parameterized sequentially using human plasma concentration, PET MOR-occupancy, and controlled isohypercapnic ventilation data, supplemented by literature-derived constraints where direct estimation was not supported. Fentanyl-MOR binding and release were modeled kinetically, whereas naloxone binding was represented by a rapid-equilibrium relationship. A 1,000-member virtual ensemble was used to propagate parameter uncertainty, and Sobol global sensitivity analysis evaluated determinants of ventilation recovery. The model reproduced the component clinical datasets used for calibration and simulated rapid ventilation recovery after IN naloxone. Simulations indicated that the apparent nasal-to-brain pathway was an important contributor to early rescue, whereas the systemic pathway contributed minimally during the first minutes after dosing. In nominal simulations, recovery began when the free brain naloxone:fentanyl molar concentration ratio reached approximately 0.063. Sobol analysis showed that fentanyl MOR affinity and brain disposition dominated very early recovery, while naloxone MOR affinity and apparent nasal-to-brain allocation became increasingly influential over the subsequent 10–15 minutes. This PK/PD framework links drug disposition, receptor competition and ventilation response in a unified model. It provides a mechanistic platform for evaluating naloxone dose, repeat-dosing, and formulation strategies while explicitly accounting for parameter uncertainty and the limitations of controlled isohypercapnic calibration data.
GS1-144 is a novel neurokinin-3 receptor (NK3R) antagonist under development for the treatment of vasomotor symptoms (VMS) associated with menopause. Suppression of luteinizing hormone (LH), a downstream marker of hypothalamic kisspeptin–neurokinin B–dynorphin (KNDy) neuronal activity, provides a measurable peripheral pharmacodynamic marker of central NK3R antagonism. The objective was to select a dose and dosing frequency for Phase II. A population pharmacokinetic–pharmacodynamic (PK-PD) model was developed using data from postmenopausal women. Individual pharmacokinetic parameter estimates were carried into a turnover model of serum LH. Model-based simulations using Bayesian estimates predicted GS1-144 and LH profiles for 7 days under once-daily doses of 30, 45, 60, and 90 mg and twice-daily doses of 15, 30, and 60 mg. Pharmacodynamic (PD) metrics included the minimum LH concentration, the maximum percentage reduction from baseline, and the LH area under the curve below baseline. GS1-144 produced dose-dependent LH suppression across once-daily and twice-daily regimens. Simulated LH profiles showed a rapid onset followed by recovery. 30 mg once daily, 60 mg once daily and 30 mg twice daily differed in depth and duration of suppression: 60 mg once daily gave the deepest suppression and 30 mg twice daily the largest integrated suppression at lower peak exposure. Integrated evaluation of absolute LH suppression, relative reduction from baseline, and sustained PD effects support GS1-144 doses of 30 mg once daily, 60 mg once daily, and 30 mg twice daily as providing pharmacologically meaningful NK3R target engagement. These regimens are recommended for Phase II evaluation in VMS associated with menopause.
Global sensitivity analysis (GSA) is a critical and widely used method for evaluating model performance, as it quantifies input variability and uncertainty in both linear and nonlinear systems, with or without parameter interactions. However, for quantitative systems pharmacology or systems biology models with complex dynamics and time-dependent output exhibiting a single dominant oscillatory frequency, the classic GSA computed on fixed-time outputs may overlook parameters controlling oscillatory behaviors. To address this, a Fourier-based approach was refined to extract a single dominant oscillatory frequency across model simulated temporal profiles and define them as the quantity of interest (QoI) to compute the Sobol indices. Surrogate modeling was used to improve computational efficiency, which reduced computation time by at least 10-fold while recovering the ranking of influential parameters. This methodology was applied to several cases, including one involving dexamethasone treatment, to showcase how drug-induced perturbations can alter parameter sensitivity. In conclusion, these cases demonstrate the utility and efficiency of a Fourier-based GSA for identifying parameters controlling a dominant frequency in oscillatory system models.
Recent guidelines recommend Bayesian forecasting for vancomycin dosing. However, the agreement and predictive performance of different pharmacokinetic models remain unclear in hospitalized patients in general. This study evaluated two model-based Bayesian approaches implemented in platforms: the Goti et al. model in DoseMeRx and the Rodvold et al. model in PrecisePK. This single-centre prospective cohort study was conducted at Sultan Qaboos University Hospital, Oman, between April and October 2025. Adult inpatients aged ≥ 18 years with normal renal function were included; patients who were critically ill, pregnant, transplant recipients or receiving renal replacement therapy, or had malignancy were excluded. Agreement between the Goti et al. and Rodvold et al. models was assessed using the concordance correlation coefficient (ρc) and weighted Cohen’s kappa (κw). Predictive performance was evaluated using relative bias (rBias) and relative root mean squared error (rRMSE). Models were considered clinically acceptable if rBias was within ± 20